AIM: DNA mismatch repair (MMR) is an important mechanism for maintaining fidelity of genomic DNA. Abnormalities in one or more MMR genes are implicated in the development of many cancers. We investigated the role of expression of MMR genes (hMLH1, hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in hepatocellular carcinogenesis. METHODS: We evaluated the expression level of MMR genes in 33 hepatocellular carcinoma (HCC) cases using the multiplex reverse transcription (RT) PCR assays, as well as in 16 cases of normal adjacent hepatic tissues. beta-actin gene was used as an internal control and calibrator for quantification of gene expression. RESULTS: Out of the 33 studied cases, 25 were HCV positive and 30 (90.9%) showed reduced expression in one or more of the studied MMR genes. Reduced expression was found in hMSH2 (71.9%), hMLH1 (53.3%), GTBP (51.1%), hPMS2 (33.3%) and hPMS1 (6%). A significant correlation was found between reduced expression of hPMS2 (P = 0.0069) and GTBP (P = 0.0034), hPMS2 and non-cirrhosis (P = 0.0197), hMLH1 and high grade. On the other hand, 57.1%, 50%, 20%, 18.8%, and 6% of the normal tissues distant to tumors showed reduced expression of hMSH2, hMLH1, GTBP, hPMS2, and hPMS1 respectively. Multivariate analysis revealed a significant correlation between the expression level of hMSH2 (P = 0.008), hMLH1 (P = 0.001) and GTBP (P = 0.032) and HCC, between hPMS2, GTBP and HCV-associated HCC (P<0.001, 0.002). CONCLUSION: Reduced expression of MMR genes seems to play an important role in HCV-associated HCC. hPMS2 is likely involved at an early stage of hepatocarcinogenesis since it was detected in normal adjacent tissues. Reduced expression of hPMS2 provides a growth advantage and stimulates proliferation which encourages malignant transformation in non-cirrhotic HCV-infected patients via acquisition of more genetic damages.
AIM: DNA mismatch repair (MMR) is an important mechanism for maintaining fidelity of genomic DNA. Abnormalities in one or more MMR genes are implicated in the development of many cancers. We investigated the role of expression of MMR genes (hMLH1, hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in hepatocellular carcinogenesis. METHODS: We evaluated the expression level of MMR genes in 33 hepatocellular carcinoma (HCC) cases using the multiplex reverse transcription (RT) PCR assays, as well as in 16 cases of normal adjacent hepatic tissues. beta-actin gene was used as an internal control and calibrator for quantification of gene expression. RESULTS: Out of the 33 studied cases, 25 were HCV positive and 30 (90.9%) showed reduced expression in one or more of the studied MMR genes. Reduced expression was found in hMSH2 (71.9%), hMLH1 (53.3%), GTBP (51.1%), hPMS2 (33.3%) and hPMS1 (6%). A significant correlation was found between reduced expression of hPMS2 (P = 0.0069) and GTBP (P = 0.0034), hPMS2 and non-cirrhosis (P = 0.0197), hMLH1 and high grade. On the other hand, 57.1%, 50%, 20%, 18.8%, and 6% of the normal tissues distant to tumors showed reduced expression of hMSH2, hMLH1, GTBP, hPMS2, and hPMS1 respectively. Multivariate analysis revealed a significant correlation between the expression level of hMSH2 (P = 0.008), hMLH1 (P = 0.001) and GTBP (P = 0.032) and HCC, between hPMS2, GTBP and HCV-associated HCC (P<0.001, 0.002). CONCLUSION: Reduced expression of MMR genes seems to play an important role in HCV-associated HCC. hPMS2 is likely involved at an early stage of hepatocarcinogenesis since it was detected in normal adjacent tissues. Reduced expression of hPMS2 provides a growth advantage and stimulates proliferation which encourages malignant transformation in non-cirrhotic HCV-infectedpatients via acquisition of more genetic damages.
Authors: Q Wei; M L Bondy; L Mao; Y Gaun; L Cheng; J Cunningham; Y Fan; J M Bruner; W K Yung; V A Levin; A P Kyritsis Journal: Cancer Res Date: 1997-05-01 Impact factor: 12.701
Authors: R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa Journal: J Clin Microbiol Date: 1990-03 Impact factor: 5.948
Authors: Abdel-Rahman N Zekri; Abeer A Bahnassy; Sabry M Shaarawy; Ossama A Mansour; Mohamed A Maduar; Hussein M Khaled; Omer El-Ahmadi Journal: J Med Microbiol Date: 2000-01 Impact factor: 2.472
Authors: A R Zekri; A A Bahnassi; B Bove; Y Huang; I H Russo; A Rogatko; S Shaarawy; O A Shawki; M R Hamza; S Omer; H M Khaled; J Russo Journal: Int J Oncol Date: 1999-10 Impact factor: 5.650
Authors: F S Leach; K Polyak; M Burrell; K A Johnson; D Hill; M G Dunlop; A H Wyllie; P Peltomaki; A de la Chapelle; S R Hamilton; K W Kinzler; B Vogelstein Journal: Cancer Res Date: 1996-01-15 Impact factor: 12.701
Authors: Sampa Pal; Stephen J Polyak; Nazneen Bano; Wan Chong Qiu; Robert L Carithers; Margaret Shuhart; David R Gretch; Aditi Das Journal: J Gastroenterol Hepatol Date: 2010-01-14 Impact factor: 4.029
Authors: Ryan A Hlady; Rochelle L Tiedemann; William Puszyk; Ivan Zendejas; Lewis R Roberts; Jeong-Hyeon Choi; Chen Liu; Keith D Robertson Journal: Oncotarget Date: 2014-10-15
Authors: Hussein M Khaled; Abeer A Bahnassy; Amira A Raafat; Abdel-Rahman N Zekri; Maha S Madboul; Nadia M Mokhtar Journal: BMC Cancer Date: 2009-01-26 Impact factor: 4.430